There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNano Genomics (BNGO – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments.
BioNano Genomics (BNGO)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on BioNano Genomics, with a price target of $6.00. The company’s shares closed last Wednesday at $1.37, close to its 52-week low of $1.19.
According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $9.75, which is a 586.6% upside from current levels. In a report issued on November 10, Scotiabank also maintained a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Ascendis Pharma (ASND)
In a report released today, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma, with a price target of $146.00. The company’s shares closed last Wednesday at $92.97.
According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Moderate Buy with an average price target of $140.80, a 49.2% upside from current levels. In a report issued on November 7, Goldman Sachs also maintained a Buy rating on the stock with a $154.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNGO:
- Bionano Genomics announces presentation of OGM Utility at AMP 2023
- Bionano Genomics downgraded to Hold from Buy at Maxim
- Bionano Genomics reports Q3 revenue $9.32M, consensus $9.08M
- Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Genomics announces OGM was included in a medical school textbook
